Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $35.6 million as the latest value for Q2 2024.

  • On a quarterly basis, Other Non-Current Liabilities rose 2596.67% to $35.6 million in Q2 2024 year-over-year; TTM through Jun 2024 was $35.6 million, a 2596.67% increase, with the full-year FY2023 number at $1.2 million, down 14.18% from a year prior.
  • Other Non-Current Liabilities was $35.6 million for Q2 2024 at Rhythm Pharmaceuticals, up from $34.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $35.6 million in Q2 2024 to a low of $1000.0 in Q1 2023.
  • A 3-year average of $8.6 million and a median of $1.3 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: decreased 16.98% in 2023, then surged 3459700.0% in 2024.
  • Rhythm Pharmaceuticals' Other Non-Current Liabilities stood at $1.3 million in 2022, then decreased by 14.18% to $1.2 million in 2023, then soared by 2995.3% to $35.6 million in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Other Non-Current Liabilities are $35.6 million (Q2 2024), $34.6 million (Q1 2024), and $1.2 million (Q4 2023).